Bvf Portfolio
Growth & qualityBVF INC/IL 13F holdings · Q3 2026 vs Q2 2026
Why growth & quality: 44 holdings, 16 effective · top 10 66% · turnover 18% a quarter · earnings yield -8.9% (median 2.9%) · 111 quarters of 13Fs
- 13F value
- $3.0bn−22.3% vs $3.9bn in Q2 2026
- Holdings
- 38 2 new · 1 sold out
- Top 10 weight
- 61.2% Largest: RVMD 16.6%
- Bought est.
- $146m New positions and adds
- Sold est.
- $660m Trims and exits
- Quarter
- Q3 2026 Filed
Largest trades since Q2 2026
Estimated dollars: the change in shares times the quarter-end price the filing implies. Exits use last quarter's value.
| Action | Stock | Shares | Est. traded | Weight | Other gurus |
|---|---|---|---|---|---|
| Sold out | XOMAGBPXOMA ROYALTY CORPORATION | −100.0% | −$323m | 8.3% → 0.0% | — |
| Trimmed | RVMDREVOLUTION MEDICINES INC | −17.0% | −$104m | 14.2% → 16.6% | 8 |
| Trimmed | IRONDISC MEDICINE INC | −79.8% | −$60m | 2.2% → 0.5% | 6 |
| Added | TYRATYRA BIOSCIENCES INC | +185.6% | +$60m | 1.2% → 3.0% | 5 |
| Trimmed | MIRMMIRUM PHARMACEUTICALS INC | −61.4% | −$55m | 3.2% → 1.1% | 8 |
| Added | STOKSTOKE THERAPEUTICS INC | +41.7% | +$28m | 2.1% → 3.1% | 4 |
| New | PYXSPYXIS ONCOLOGY INC | New | +$28m | 0.0% → 0.9% | 2 |
| Trimmed | XNCRXENCOR INC | −12.7% | −$23m | 2.9% → 5.1% | 4 |
| Trimmed | GPCRSTRUCTURE THERAPEUTICS INC | −20.1% | −$21m | 4.6% → 2.8% | 5 |
| Trimmed | KURAKURA ONCOLOGY INC | −20.8% | −$19m | 2.4% → 2.4% | 3 |
| New | ALECALECTOR INC | New | +$19m | 0.0% → 0.6% | 3 |
| Trimmed | AVTXAVALO THERAPEUTICS INC | −56.3% | −$18m | 1.0% → 0.5% | 5 |
| Trimmed | NKTRNEKTAR THERAPEUTICS | −10.8% | −$16m | 4.3% → 4.2% | 1 |
| Added | SGMTSAGIMET BIOSCIENCES INC | +40.0% | +$9.9m | 0.5% → 1.1% | 3 |
| Trimmed | PVLAPALVELLA THERAPEUTICS INC NE | −9.8% | −$9.1m | 2.6% → 2.8% | 2 |
| Trimmed | ZYMEZYMEWORKS INC | −5.1% | −$4.9m | 2.4% → 3.0% | 2 |
| Added | OKURONKURE THERAPEUTICS INC | +25.0% | +$2.2m | 0.4% → 0.4% | 2 |
| Trimmed | GLUEMONTE ROSA THERAPEUTICS INC | −4.1% | −$2.2m | 2.8% → 1.7% | 4 |
| Trimmed | IMCRIMMUNOCORE HLDGS PLC | −4.9% | −$1.9m | 1.1% → 1.2% | 4 |
| Trimmed | XFORX4 PHARMACEUTICALS INC | −29.4% | −$1.9m | 0.3% → 0.2% | 1 |
| Trimmed | ANNXANNEXON INC | −4.8% | −$1.8m | 1.3% → 1.2% | 1 |
| Trimmed | TENXTENAX THERAPEUTICS INC | −92.6% | −$594k | 0.1% → 0.0% | 0 |
All holdings 38 identified, plus $483m in securities without a listed ticker
Click a column to sort. Values are as reported at quarter-end, not today's prices.
| # | Stock | Shares | ||||
|---|---|---|---|---|---|---|
| 1 | RVMDREVOLUTION MEDICINES INC | $505m | 2,460,560 | −17.0% | 8 | |
| 2 | KYMRKYMERA THERAPEUTICS INC | $433m | 3,872,052 | Unchanged | 3 | |
| 3 | MLTXMOONLAKE IMMUNOTHERAPEUTICS | $187m | 16,001,284 | Unchanged | 2 | |
| 4 | XNCRXENCOR INC | $155m | 6,227,034 | −12.7% | 4 | |
| 5 | NKTRNEKTAR THERAPEUTICS | $129m | 2,134,007 | −10.8% | 1 | |
| 6 | STOKSTOKE THERAPEUTICS INC | $94m | 3,608,968 | +41.7% | 4 | |
| 7 | TYRATYRA BIOSCIENCES INC | $92m | 4,215,886 | +185.6% | 5 | |
| 8 | ZYMEZYMEWORKS INC | $92m | 3,464,142 | −5.1% | 2 | |
| 9 | CGEMCULLINAN THERAPEUTICS INC | $88m | 5,750,683 | Unchanged | 3 | |
| 10 | GPCRSTRUCTURE THERAPEUTICS INC | $84m | 2,691,426 | −20.1% | 5 | |
| 11 | PVLAPALVELLA THERAPEUTICS INC NE | $84m | 607,149 | −9.8% | 2 | |
| 12 | KURAKURA ONCOLOGY INC | $72m | 6,690,108 | −20.8% | 3 | |
| 13 | GLUEMONTE ROSA THERAPEUTICS INC | $51m | 4,276,578 | −4.1% | 4 | |
| 14 | OLMAOLEMA PHARMACEUTICALS INC | $46m | 5,295,893 | Unchanged | 2 | |
| 15 | FDMT4D MOLECULAR THERAPEUTICS IN | $41m | 2,879,289 | Unchanged | 3 | |
| 16 | IMCRIMMUNOCORE HLDGS PLC | $37m | 1,230,909 | −4.9% | 4 | |
| 17 | ANNXANNEXON INC | $35m | 8,278,164 | −4.8% | 1 | |
| 18 | MIRMMIRUM PHARMACEUTICALS INC | $35m | 407,226 | −61.4% | 8 | |
| 19 | SGMTSAGIMET BIOSCIENCES INC | $35m | 3,500,000 | +40.0% | 3 | |
| 20 | PYXSPYXIS ONCOLOGY INC | $28m | 11,826,140 | New | 2 | |
| 21 | ABSIABSCI CORPORATION | $25m | 2,361,674 | Unchanged | 2 | |
| 22 | IVVDINVIVYD INC | $25m | 28,165,000 | Unchanged | 2 | |
| 23 | AVRANTERIS TECHNOLOGIES GLOBAL | $23m | 3,000,000 | Unchanged | 4 | |
| 24 | FHTXFOGHORN THERAPEUTICS INC | $21m | 5,842,000 | Unchanged | 1 | |
| 25 | STROSUTRO BIOPHARMA INC | $20m | 1,251,788 | Unchanged | 3 | |
| 26 | QTTBQ32 BIO INC | $19m | 2,350,000 | Unchanged | 3 | |
| 27 | ALECALECTOR INC | $19m | 10,046,206 | New | 3 | |
| 28 | ELDNELEDON PHARMACEUTICALS INC | $16m | 6,293,282 | Unchanged | — | |
| 29 | IRONDISC MEDICINE INC | $15m | 233,300 | −79.8% | 6 | |
| 30 | AVTXAVALO THERAPEUTICS INC | $14m | 907,406 | −56.3% | 5 | |
| 31 | OKURONKURE THERAPEUTICS INC | $11m | 4,045,278 | +25.0% | 2 | |
| 32 | IMUXIMMUNIC INC | $7.1m | 765,295 | Unchanged | — | |
| 33 | MOLNMOLECULAR PARTNERS AG | $5.2m | 1,353,968 | Unchanged | 1 | |
| 34 | IMAIMAGENEBIO INC | $5.1m | 1,110,002 | Unchanged | 1 | |
| 35 | XFORX4 PHARMACEUTICALS INC | $4.6m | 1,576,624 | −29.4% | 1 | |
| 36 | IVAINVENTIVA SA | $2.5m | 686,040 | Unchanged | 1 | |
| 37 | TCRXTSCAN THERAPEUTICS INC | $1.7m | 5,564,290 | Unchanged | 1 | |
| 38 | TENXTENAX THERAPEUTICS INC | $47k | 25,000 | −92.6% | — |
Closest portfolios
Overlap is the weight two books have in common: for each shared stock, the smaller of the two weights, summed.
- Paradigm Biocapital Advisors20.5%5 shared · RVMD, TYRA, OLMA, GPCR
- Baker Bros. Advisors16.2%13 shared · RVMD, KYMR, GLUE, GPCR
- Avoro Capital Advisors15.7%4 shared · KYMR, RVMD, GPCR, AVTX
- Farallon Capital Management14.8%4 shared · RVMD, AVTX, IMCR, SGMT
- Deerfield Management9.1%9 shared · RVMD, STOK, GPCR, IRON
- TCG Crossover Management7.7%8 shared · TYRA, XNCR, GLUE, MIRM
- Montanova Capital6.4%5 shared · PVLA, KURA, GLUE, AVR
- Ra Capital Management6.2%12 shared · TYRA, XNCR, FDMT, IRON
- Rtw Investments5.9%8 shared · XNCR, STOK, IMCR, GPCR
- Frazier Life Sciences Management5.3%5 shared · PVLA, MIRM, IMCR, IRON
Only here
The largest holdings no other tracked guru owns.
- ELDNELEDON PHARMACEUTICALS INC0.5%
- IMUXIMMUNIC INC0.2%
- TENXTENAX THERAPEUTICS INC0.0%
A 13F is a filing, not a live portfolio. It lists US-listed long stock positions at quarter-end, and it arrives up to 45 days later. Cash, shorts, bonds, options and foreign listings are not in it. Trade sizes here are estimates from the change in share count, restated for stock splits.
Snapshot refreshed